Absci Reports Business Updates and Third Quarter 2026 Financial and Operating Results

(NASDAQ:ABSI) Absci Corporation reported financial and operating results for the quarter ended September 30, 2026. The company is advancing ABS-201, a prolactin receptor inhibitor, for pattern hair loss (PHL) and endometriosis, with the HEADLINE Phase 1/2a trial ongoing for PHL and the planned STORYLINE Phase 2 trial for endometriosis expected to initiate in mid-2027. Absci anticipates reporting 13-week interim proof-of-concept data for ABS-201 in December 2026 and full 26-week data in early 2027. The company appointed Gerry Muhle, former Galderma executive, as Chief Commercial Officer, bringing over 25 years of experience in pharma, aesthetics, and consumer brands. For the three months ended September 30, 2026, revenue was $0.3 million, compared to $0.4 million for the same period in 2025. Research and development expenses were $23.6 million, up from $19.2 million in the prior year period, primarily due to advancement of internal programs and external nonclinical and clinical development of ABS-201. Selling, general, and administrative expenses were $9.0 million, compared to $8.4 million, mainly due to stock-based compensation. Net loss for the quarter was $33.3 million, compared to $28.7 million in the prior year period. Cash, cash equivalents, and marketable securities as of September 30, 2026, were $173.7 million, down from $201.1 million as of June 30, 2026. The company believes its cash, cash equivalents, and marketable securities will be sufficient to fund operating plans into the second half of 2028. For the nine months ended September 30, 2026, revenue was $0.8 million, research and development expenses were $65.5 million, selling, general, and administrative expenses were $27.3 million, and net loss was $96.1 million. As of September 30, 2026, total assets were $239.6 million and total liabilities were $20.9 million. The company had 171,799,223 weighted-average common shares outstanding for the quarter. Recent scientific presentations included data on ABS-201's mechanism and efficacy in hair growth and endometriosis models at major conferences. The company continues to advance its internal pipeline and partnered programs, including ABS-202, an anti-PRLR antibody in preclinical development for an undisclosed I&I indication. Absci is headquartered in Vancouver, WA, with AI Research Labs in New York City and Serbia, and an Innovation Center in Switzerland.

Absci Appoints Gerry Muhle as Chief Commercial Officer to Build Category-Defining Brands for ABS-201 and Its Broader Pipeline

(NASDAQ:ABSI) Absci Corporation announced the appointment of Gerry Muhle as Chief Commercial Officer. Gerry Muhle will lead Absci’s commercial strategy, focusing on advancing ABS-201 and the company’s broader pipeline. Mr. Muhle brings over 25 years of commercial leadership experience, having led multiple successful product launches across prescription medicines, aesthetics, and consumer skincare, and held full P&L responsibility for major businesses at his previous companies. He joins Absci from Galderma, where he served as Senior Vice President and Head of Global Product Strategy, leading global commercial and product strategy across Therapeutic Dermatology, Injectable Aesthetics, and Dermatological Skincare. At Galderma, Mr. Muhle expanded brands such as Dysport, Sculptra, and Cetaphil, and brought new therapies including Nemluvio and Relfydess to market. Previously, he led international strategic marketing at Allergan/AbbVie for an aesthetics portfolio that included Botox (R) and Juvéderm (R). His earlier career at GSK included roles in cardiometabolic disease, respiratory medicine, rare diseases, and neuroscience, where he served as Vice President and Head of the Neurosciences Centre of Excellence. Sean McClain, Founder & CEO of Absci, stated that Mr. Muhle’s experience in commercializing prescription medicines and building consumer brands will shape Absci’s commercial strategy, particularly for ABS-201 in pattern hair loss and endometriosis. Mr. Muhle expressed enthusiasm for leveraging his experience to build and execute Absci's commercial strategy. Absci believes that ABS-201’s novel regenerative mechanism has the potential to create a new category of durable hair-regrowth treatment. ABS-201 is also being investigated as a potential “best-in-class” therapeutic for endometriosis. Absci anticipates reporting 13-week interim proof-of-concept data for ABS-201 in December 2026. The company is headquartered in Vancouver, WA, with AI Research Labs in New York City and Serbia, and an Innovation Center in Switzerland.